Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression

Citation
R. Pratiwi et al., Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression, J HEPATOL, 31(1), 1999, pp. 39-46
Citations number
44
Categorie Soggetti
Gastroenerology and Hepatology","da verificare
Journal title
JOURNAL OF HEPATOLOGY
ISSN journal
01688278 → ACNP
Volume
31
Issue
1
Year of publication
1999
Pages
39 - 46
Database
ISI
SICI code
0168-8278(199907)31:1<39:LDAIAH>2.0.ZU;2-K
Abstract
Background/Aims:Hereditary haemochromatosis shows a wide variation in pheno typic expression, which is thought to be due, in part, to genetic factors. A single missense mutation in HFE, leading to an amino acid substitution (C 282Y) has been shown to be the causative mutation, clearly responsible for clinical expression of the disorder. Since homozygosity for the C282Y mutat ion can give rise to a disorder which shows wide variation in clinical expr ession, we investigated the possibility that genetic modifiers of HFE may e xist. Methods: Linkage disequilibrium analysis was performed on chromosome 6p21,3 in 74 patients homozygous for the C282Y mutation using microsatellite mark ers spanning the haemochromatosis gene region. Phenotypic expression was ev aluated based on transferrin saturation, serum ferritin, hepatic iron conce ntration and index, and iron grade. Results: Linkage disequilibrium (LD) analysis showed a predominant ancestra l haplotype from D6S265 to D6S2236 covering a region of approximately 5 Mb. The overall LD distribution in this region showed two peaks of highly sign ificant association at D6S105 (2 Mb proximal to HFE) and at D6S2239 approxi mately 50 kb distal to HFE. Male patients homozygous for D6S105 allele 8, h ad significantly higher hepatic iron indices than patients heterozygous or nullizygous for D6S105-8 (p<0,038), Conclusion: This analysis indicates that modifying gene(s) or another mutat ion affecting HHC clinical expression may be located in the region of D6S10 5.